Mutation E522K in human DNA topoisomerase IIβ confers resistance to methyl N-(4′-(9-acridinylamino)-phenyl)carbamate hydrochloride and methyl N-(4′-(9-acridinylamino)-3-methoxy-phenyl) methane sulfonamide but hypersensitivity to etoposide

Molecular Pharmacology

Volumn 66, Issue 3, 2004, Pages 430-439

  Leontiou, Chrysoula ^a   Lakey, Jeremy H ^a   Austin, Caroline A ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIDINE; BETAE522K PROTEIN; COMPLEMENTARY DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); ELLIPTICINE; ETOPOSIDE; HYDROXYLAMINE; METHYL N (4 (9 ACRIDINYLAMINO) 3 METHOXY PHENYL); METHYL N (4 (9 ACRIDINYLAMINO) PHENYL)CARBAMATE HYDROCHLORIDE; UNCLASSIFIED DRUG;

ARTICLE; CROSS RESISTANCE; DNA CLEAVAGE; DRUG SENSITIVITY; GENE MUTATION; HYPERSENSITIVITY; MUTAGENESIS; MUTAGENIC ACTIVITY; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN STABILITY; TEMPERATURE SENSITIVITY; WILD TYPE; YEAST;

AMINO ACID SEQUENCE; AMSACRINE; ANTINEOPLASTIC AGENTS; DNA; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; ENZYME STABILITY; ETOPOSIDE; GLUTAMIC ACID; HUMANS; LYSINE; MODELS, MOLECULAR; MUTATION; TRANEXAMIC ACID;

EID: 4944256960     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Aravind L, Leipe DD, and Koonin EV (1998) Toprim - a conserved catalytic domain in type 1A and II topoisomerases, DnaG-type primases, OLD family nucleases and RecR proteins. Nucleic Acids Res 26:4205-4213.
2. Austin CA, Marsh KL, Wasserman RA, Willmore E, Sayer PJ, Wang JC, and Fisher LM (1995) Expression, domain structure and enzymatic properties of an active recombinant human DNA topoisomerase IIbeta. J. Biol. Chemistry 270:15739-15746.
3. Baguley BC, Leteurtre F, Riou JF, Finlay GJ, and Pommier Y (1997) A carbamate analogue of amsacrine with activity against non-cycling cells stimulates topoisomerase II cleavage at DNA sites distinct from those of amsacrine. Eur J Cancer 33:272-279.
4. Bakic M, Beran M, Andersson BS, Silberman L, Estey E and Zwelling LA (1986) The production of topoisomerase II-mediated DNA cleavage in human leukemia cells predicts their susceptibility to 4′-(9-acridinylamino) methanesulfon-m-anisidide (m-AMSA). Biochem Biophys Res Commun 134:638-645.
5. Berger JM, Gamblin SJ, Harrison SC, and Wang JC (1996) Structure and mechanism of DNA topoisomerase II. Nature (Lond) 379:225-232.
6. Berger JM, Fass D, Wang JC, and Harrison SC (1998) Structural similarities between topoisomerases that cleave one or both DNA strands. Proc Natl Acad Sci USA 95:7876-7881.
7. Chan VTW, Ng SW, Eder PJ, and Schnipper LE (1993) Molecular cloning and identification of a point mutation in the topoisomerase II cDNA from an etoposide resistant Chinese hamster ovary cell line. J Biol Chem 268:2160-2165.
8. Creighton TE (1993) Proteins: Structures and Molecular Properties, 2nd ed. W.H. Freeman and Co., New York.
9. r 170,000 isozyme of DNA topoisomerase II in human tumor cells. Cancer Res 53:1373-1379.
10. Dereuddre S, Delaporte C, and Jacquemin-Sablon A (1997) Role of topoisomerase II beta in the resistance of 9-OH-ellipticine-resistant Chinese hamster fibroblasts to topoisomerase II inhibitors. Cancer Res 57:4301-4308.
11. Elsea SH, Hsiung Y, Nitiss JL, and Osheroff N (1995) A yeast type II topoisomerase selected for resistance to quinolones. Mutation of histidine 1012 to tyrosine confers resistance to nonintercalative drugs but hypersensitivity to ellipticine. J Biol Chem 270:1913-1920.
12. Errington F, Willmore E, Tilby MJ, Li L, Li G, Li W, Baguley BC, and Austin CA (1999) Murine transgenic cells lacking DNA topoisomerase IIβ are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation. Mol Pharmacol 56:1309-1316.
13. Errington F, Willmore E, Leontiou C, Tilby MJ, and Austin CA (2004) Differences in the longevity of topo IIalpha and beta drug stabilized cleavable complexes and the relationship to drug sensitivity. Cancer Chemother Pharmacol 53:155-162.
14. Fass D, Bogden CE, and Berger JM (1999) Quaternary changes in topoisomerase II may direct orthogonal movement of two DNA strands. Nat Struct Biol 6:322-326.
15. Finlay GJ, Holdaway KM, and Baguley BC (1994) Novel carbamate analogues of amsacrine with activity against non-cycling murine and human tumour cells. Cancer Chemother Pharmacol 34:159-165.
16. Freudenreich CH, Chang C, and Kreuzer KN (1998) Mutations in the bacteriophage T4 type II DNA topoisomerase that alter sensitivity to antitumor agent 4′-(9-acridinylamino)methanesulfon-m-anisidide and an antibacterial quinolone. Cancer Res 58:1260-1267.
17. Herzog CE, Holmes KA, Tuschong LM, Ganapathi R, and Zwelling LA (1998) Absence of topoisomerase IIβ in an amsacrine-resistant human leukemia cell line with mutant topoisomerase IIα. Cancer Res 58:5298-5300.
18. Hinds M, Deisseroth K, Mayes J, Altschuler E, Jansen R, Ledley FD, and Zwelling LA (1991) Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of topoisomerase II. Cancer Res 51:4729-4731.
19. Huff AC and Kreuzer KN (1990) Evidence for a common mechanism of action for antitumor and antibacterial agents that inhibit type II DNA topoisomerase. J Biol Chem 265:20496-20505.
20. Hsiung Y, Elsea SH, Osheroff N, and Nitiss JL (1995) A mutation in yeast TOP2 homologous to a quinolone-resistant mutation in bacteria. J Biol Chem 270:20359-20364.
21. Kaufmann SH (1998) Cell death induced by topoisomerase-targeted drugs: more questions than answers. Biochim Biophys Acta 1400:195-211.
22. Kubo A, Yoshikawa A, Hirashima T, Masuda N, Takada M, Fukuoka M, and Nagagawa K (1996) Point mutations of the topoisomerase IIα gene in patients with small cell lung cancer treated with etoposide Cancer Res 56:1232-1236.
23. Lee MS, Wang JC, and Beran M (1992) Two independent amsacrine-resistant human myeloid leukemia cell lines share an identical point mutation in the 170 KDa form of human topoisomerase II. J Mol Biol 223:837-843.
24. Leontiou C, Lighthowlers RN, Lakey JH, and Austin CA. Kinetic analysis of DNA binding of DNA topoisomerase IIalpha and beta by surface plasmon resonance. (2003) FEBS Lett 554:206-210.
25. Liu Q and Wang JC (1999) Similarity in the catalysis of DNA breakage and rejoining by type IA and IIA DNA topoisomerases. Proc Natl Acad Sci USA 96:881-886.
26. Marsh KL, Willmore E, Tinelli S, Cornarotti M, Meczes EL, Capranico G, Fisher LM, and Austin CA (1996) Amsacrine-promoted DNA cleavage site determinants for the two human DNA topoisomerase II isoforms alpha and beta. Biochem Pharmacol 52:1675-1685.
27. Meczes EL, Marsh KL, Fisher LM, Rogers MP, and Austin CA (1997) Complementation of temperature sensitive topoisomerase II mutations in S. cerevisiae by a human TOP2β construct allows study of topoisomerase IIβ inhibitors in yeast. Cancer Chemother Pharmacol 39:367-375.
28. Morais Cabral JH, Jackson AP, Smith CV, Shikotra N, Maxwell A, and Liddington RC (1997) Crystal structure of the breakage - reunion domain of DNA gyrase. Nature (Lond) 388:903-906.
29. Nitiss JL (1994) Using yeast to study resistance to topoisomerase II-targeting drugs. Cancer Chemother Pharmacol 34(Suppl):S6-S13.
30. Noble CG and Maxwell A (2002) The role of GyrB in the DNA cleavage-religation reaction of DNA gyrase: a proposed two metal-ion mechanism. J Mol Biol 318:361-371.
31. Osheroff N and Zechiedrich EL (1987) Calcium-promoted DNA cleavage by eukaryotic topoisomerase II: trapping the covalent enzyme-DNA complex in an active form. Biochemistry 26:4303-4309.
32. Patel S, Keller BA, and Fisher LM (2000) Mutations at Arg486 and Glu571 in human topoisomerase IIα confer resistance to amsacrine: relevance for antitumor drug resistance in human cells. Mol Pharmacol 57:784-791.
33. Sali A and Blundell TL (1993) Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 234:779-815.
34. Strumberg D, Nitiss JL, Dong J, Kohn KW, and Pommier Y (1999a) Molecular analysis of yeast and human type II topoisomerases. Enzyme-DNA and drug interactions. J Biol Chem 274:28246-28255.
35. Strumberg D, Nitiss JL, Rose A, Nicklaus MC, and Pommier Y (1999b) Mutation of a conserved serine residue in a quinolone-resistant type II topoisomerase alters the enzyme-DNA and drug interactions. J Biol Chem 274:7292-7301.
36. Turnbull RM, Meczes EL, Rogers MP, Lock RB, Sullivan DM, Finlay GJ, Baguley BC, and Austin CA (1999) Carbamate analogues of amsacrine active against non-cycling cells: relative activity against topoisomerases IIalpha and beta. Cancer Chemother Pharmacol 44:275-282.
37. Wasserman RA and Wang JC (1994) Analysis of yeast DNA topoisomerase II mutants resistant to the antitumor drug amsacrine. Cancer Res 54:1795-1800.
38. West KL, Meczes EL, Thorn R, Turnbull RM, Marshall R, and Austin CA (2000) Mutagenesis of E477 or K505 in the B′ domain of human topoisomerase II beta increases the requirement for magnesium ions during strand passage. Biochemistry 39:1223-1233.
39. Yoshida H, Bogaki M, Nakamura M, Yamanaka LM, and Nakamura S (1991) Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli. Antimicrob Agents Chemother 35:1647-1650.